Results for this period
First quarter1 April 2026 to 30 June 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。
Revenue from blood collection tube preparation equipment and systems exceeded the level recorded in the same period of the previous year. In the same period of the previous year, there were few sales opportunities in the domestic market, and the market environment for specimen testing equipment remained challenging because of intense competition. Despite being affected by shortages of raw materials and other factors, the company worked to maintain a stable supply of consumables and other products.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥2,202,353 thousand (YoY +25.3%) |
| Operating profit | ¥236,710 thousand |
| Ordinary income | ¥243,920 thousand (YoY +937.2%) |
| Profit attributable to owners of the parent | ¥158,993 thousand (YoY +864.7%) |
| Equity ratio | End of the current fiscal period 84.4 / End of previous period Not disclosed |
| Total assets | ¥16,239,684 thousand |
| Net assets | ¥13,709,484 thousand |
| Revision to Earnings Forecast | Net Sales ¥4,270 million → ¥4,360 million（+2.1%） / Operating profit ¥170 million → ¥300 million（+76.5%） / Ordinary income ¥170 million → ¥310 million（+82.4%） / Net income ¥120 million → ¥220 million（+83.3%） |
| Regional sales | Blood collection tube preparation equipment and systems Domestic ¥634,913 thousand (YoY +136.3%) / Overseas expansion ¥84,965 thousand (YoY -6.8%) / Specimen Testing Equipment Domestic ¥61,878 thousand (YoY -8.0%) / Overseas expansion ¥41,616 thousand (YoY -22.9%) / Consumables and other products Domestic ¥1,183,592 thousand (YoY +5.8%) / Overseas expansion ¥195,388 thousand (YoY +24.4%) / Overseas revenue ratio 14.6 % |
| Depreciation and amortization | ¥21,437 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income No applicable matters / Extraordinary loss No applicable matters |
| Disclosure regarding the going concern assumption | No applicable matters |
| Factors Behind Changes in Business Performance | Revenue from blood collection tube preparation equipment and systems exceeded the level recorded in the same period of the previous year. In the same period of the previous year, there were few sales opportunities in the domestic market, and the market environment for specimen testing equipment remained challenging because of intense competition. Despite being affected by shortages of raw materials and other factors, the company worked to maintain a stable supply of consumables and other products. |
Items this document does not state (21)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This reflects expected increased sales of consumables and other products in Japan and overseas in the second quarter, as well as lower selling, general and administrative expenses because research and development expenses were incurred later than initially expected. These effects are not expected to affect full-year results.